abstract |
The present invention relates to an unsaturated fatty acid-conjugated CP2c-targeting peptide-based anticancer agent. In the present invention, when conjugated with an unsaturated fatty acid, ACP52C, which is a leading CP2c-targeting peptide substance exhibiting an effect as a general-purpose anticancer agent, was found to improve in-vivo stability without affecting the anticancer effect. It was also observed to have cancer cell-specific anticancer efficacy in various cancer cells and normal cells. |